At the time of writing, Nurix Therapeutics Inc [NRIX] stock is trading at $25.16, up 6.47%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NRIX shares have gain 16.81% over the last week, with a monthly amount glided 1.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on October 11, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. On July 31, 2024, Truist initiated with a Buy rating and assigned a price target of $36 on the stock. Barclays initiated its recommendation with a Overweight and recommended $20 as its price target on March 09, 2023. Oppenheimer started tracking with a Outperform rating for this stock on February 28, 2023, and assigned it a price target of $25. In a note dated October 11, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $11 on this stock.
For the past year, the stock price of Nurix Therapeutics Inc fluctuated between $4.22 and $26.31. Currently, Wall Street analysts expect the stock to reach $29.78 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $25.16 at the most recent close of the market. An investor can expect a potential return of 18.36% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
According to Nurix Therapeutics Inc [NASDAQ:NRIX], the company’s sales were 56.42M for trailing twelve months, which represents an -31.84% plunge. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.63 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.74 points at the first support level, and at 22.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.08, and for the 2nd resistance point, it is at 27.00.
Ratios To Look Out For
It is important to note that Nurix Therapeutics Inc [NASDAQ:NRIX] has a current ratio of 5.28. Also, the Quick Ratio is 5.28, while the Cash Ratio stands at 1.15. Considering the valuation of this stock, the price to sales ratio is 28.72, the price to book ratio is 4.48.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Oct 01 ’24 when 5760.0 shares were sold. Officer, CHRISTINE RING completed a deal on Oct 01 ’24 to buy 9050.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 9050.0 shares on Sep 03 ’24.
